SCHEMBL24601081

SCHEMBL24601081

CNC(=O)[C@H]1O[C@@H](n2cnc3c(NC)nc(-c4cncc(Cl)c4)nc32)[C@H](O)[C@@H]1O

nearest known ligand 0.69

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 18/20 0.69
▸ ADORA1 P30542 7/20 0.64
▸ ADORA2B P29275 2/20 0.64
▸ ADORA2A P29274 4/20 0.57
▸ ADRA2A P08913 1/20 0.57
▸ TMIGD3 P0DMS9 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29073829 1.00 ADORA3 (0.69) ADORA3ADORA1ADORA2BADORA2AADRA2A
SCHEMBL29762086 1.00 ADORA3 (0.69) ADORA3ADORA1ADORA2BADORA2AADRA2A
SCHEMBL29073825 1.00 ADORA3 (0.69) ADORA3ADORA1ADORA2BADORA2AADRA2A
SCHEMBL29073619 0.92 ADORA3 (0.61) ADORA3ADORA1ADORA2BADORA2A
SCHEMBL29762083 0.92 ADORA3 (0.61) ADORA3ADORA1ADORA2BADORA2A
SCHEMBL26628628 0.92 ADORA3 (0.58) ADORA3ADORA1ADORA2BADORA2AADRA2A
SCHEMBL24600610 0.92 ADORA3 (0.61) ADORA3ADORA1ADORA2BADORA2A
SCHEMBL29073625 0.92 ADORA3 (0.61) ADORA3ADORA1ADORA2BADORA2A
SCHEMBL30850739 0.92 ADORA3 (0.58) ADORA3ADORA1ADORA2BADORA2AADRA2A
SCHEMBL24601148 0.92 ADORA3 (0.58) ADORA3ADORA1ADORA2BADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2024-04-11 — — US claimed
EP-4273153-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2023-11-08 — — EP claimed
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2024-04-11 — — US disclosed
EP-4273153-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2023-11-08 — — EP disclosed
EP-4273153-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) 2023-11-08 — — EP disclosed
WO-2022143740-A1 ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF 浙江春禾医药科技有限公司 2022-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116975-A1 ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF ADORA3, ADORA2A, ADORA2B ADORA3 1/4885ADORA1 4/4885ADORA2B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback